Multiple sclerosis drug metabolite appears to slow Parkinson’s disease onset: Study
The metabolite of a multiple sclerosis drug appears to slow the onset of Parkinson’s disease. The drug dimethylfumarate, or DMF, as well as its metabolite monomethylfumarate, or MMF, both increase activity of Nrf2, a protein that helps protect the body from oxidative stress and inflammation characteristic of both multiple sclerosis and Parkinson’s disease, according to ...click here to read more
